Edward V. Loftus, Jr., MD, FACG

Mayo Clinic College of Medicine and Science
Rochester, Minnesota

Disclosure information not submitted.

Presentation(s):

• B0379 - Active Tuberculosis and Opportunistic Infections: Pooled Safety Analysis of Ustekinumab Through up to 5 Years Across All Approved Indications

  Monday, October 24, 2022
  10:00 AM – 12:00 PM ET

• B0375 - Efficacy and Safety of Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Crohn’s Disease: Results From a Randomized Phase 3 U-EXCEL Study

  Monday, October 24, 2022
  10:00 AM – 12:00 PM ET

• B0378 - Fatigue Improvement Correlates With Reductions in Work Productivity Impairment and Related Indirect Cost in Patients With Crohn’s Disease: Post Hoc Analysis of Phase 3 Rizankizumab Induction Trials

  Monday, October 24, 2022
  10:00 AM – 12:00 PM ET

• B0377 - Mirikizumab Significantly Improves Abdominal Pain in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies

  Monday, October 24, 2022
  10:00 AM – 12:00 PM ET

• B0376 - Risankizumab Results in Improvements in Disease Activity Scores in Patients With Crohn’s Disease: Post-Hoc Analysis of the Phase 3 Induction and Maintenance Studies

  Monday, October 24, 2022
  10:00 AM – 12:00 PM ET